CN103690922B - A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome - Google Patents
A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome Download PDFInfo
- Publication number
- CN103690922B CN103690922B CN201310739992.5A CN201310739992A CN103690922B CN 103690922 B CN103690922 B CN 103690922B CN 201310739992 A CN201310739992 A CN 201310739992A CN 103690922 B CN103690922 B CN 103690922B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- polycystic ovarian
- ovarian syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition for the treatment of polycystic ovarian syndrome, said composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 26-36 part, Rhizoma Zingiberis 8-14 part, Ramulus Euonymi 26-36 part, Pseudobulbus Cremastrae Seu Pleiones 18-25 part, Radix Morindae Officinalis 18-25 part, Folium Artemisiae Argyi 8-14 part, Fructus Tribuli 8-14 part, Fructus Arctii 8-14 part, Herba Asari 18-25 part, Semen Coicis 26-36 part.Adopt traditional Chinese medicine composition for treating polycystic ovarian syndrome of the present invention to improve pregnancy rate, short ovary ovulation and menorrhea are risen, and safeguard homeostasis, improve cure rate.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome, belong to technical field of Chinese medicines.
Background technology
Polycystic ovarian syndrome (Polycystic Ovary Syndrome) is the modal endocrine regulation disease of gynecological, its etiology unknown, with Chronic anovulation (or rare send a manuscript to the compositor ovum), insulin resistant (Insulin Resistance, IR) and hyperandrogenism (Hyperandrogenism) clinical syndrome that is feature, be period of duration female acyesis, menoxenia most commonly encountered diseases because of one of.Its pathogenesis is complicated, thinks heredity (gene mutation) and the coefficient result of environment at present.At society due to factors such as people's operating pressure is large, rhythm of life fast, Bad Eating Habit, increasing women is made to suffer from this disease.Polycystic ovarian syndrome Epidemiological study in the past shows that its sickness rate is 5% ~ 10%; Western medical treatment is based on hormone therapy, and curative effect is unstable, and side effect is large.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition of more safe and reliable treatment polycystic ovarian syndrome.
The object of the present invention is achieved like this:
Treat a Chinese medicine composition for polycystic ovarian syndrome, be prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 26-36 part, Rhizoma Zingiberis 8-14 part, Ramulus Euonymi 26-36 part, Pseudobulbus Cremastrae Seu Pleiones 18-25 part, Radix Morindae Officinalis 18-25 part, Folium Artemisiae Argyi 8-14 part, Fructus Tribuli 8-14 part, Fructus Arctii 8-14 part, Herba Asari 18-25 part, Semen Coicis 26-36 part.
Preferably you, the Chinese medicine composition of described treatment polycystic ovarian syndrome as above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 30-32 part, Rhizoma Zingiberis 10-12 part, Ramulus Euonymi 30-32 part, Pseudobulbus Cremastrae Seu Pleiones 20-23 part, Radix Morindae Officinalis 20-23 part, Folium Artemisiae Argyi 10-12 part, Fructus Tribuli 10-12 part, Fructus Arctii 10-12 part, Herba Asari 20-23 part, Semen Coicis 30-32 part.
In the present invention's most preferred embodiment, Chinese medicine composition as above is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 30 parts, Rhizoma Zingiberis 12 parts, Ramulus Euonymi 30 parts, Pseudobulbus Cremastrae Seu Pleiones 22 parts, Radix Morindae Officinalis 22 parts, Folium Artemisiae Argyi 12 parts, Fructus Tribuli 12 parts, Fructus Arctii 12 parts, Herba Asari 22 parts, Semen Coicis 30 parts.
Further preferably, the Chinese medicine composition for the treatment of polycystic ovarian syndrome as above is oral formulations.
Again further preferably, the Chinese medicine composition for the treatment of polycystic ovarian syndrome as above is oral liquid, granule, tablet or capsule.
Found by clinical application research, the medicine composite for curing polycystic ovarian syndrome be prepared from by above-mentioned Chinese crude drug can improve pregnancy rate, and short ovary ovulation and menorrhea are risen, and safeguard homeostasis, improve cure rate.Therefore, second object of the present invention is to provide a kind of new medical use, the application of namely above-mentioned Chinese medicine composition in the Chinese medicine of preparation treatment polycystic ovarian syndrome.
Chinese crude drug of the present invention has following source: Caulis Spatholobi is selected from the dry rattan of pulse family Leguminosae plant spatholobus suberectus Spatholobus suberectusDunn; Rhizoma Zingiberis selects the dry rhizome of zingiber Zingiber officinale Rosc.; Ramulus Euonymi is winged euonymus again, Celastraceae burning buss winged euonymus Euonymus alatus (Thunb.) Sieb., and with root, branch and the leaf of band wing are used as medicine; Pseudobulbus Cremastrae Seu Pleiones selects the dry pseudobulb of orchid Pleione yunnanensis P. yunnansis Rolfe; Radix Morindae Officinalis selects the dry root of Maguireothamnus speciosus Radix Morindae Officinalis Morinda officinalis How; Folium Artemisiae Argyi selects the dried leaves of feverfew Chinese mugwort Artemisia argyi Levl. et Vant.; Fructus Tribuli selects the dry mature fruit of zygophyllaceae plant Fructus Tribuli Tribulus terrestris L.; Fructus Arctii is selected from the dry mature fruit of feverfew Fructus Arctii Arctium lappa L.; Herba Asari selects the whole herb with root of aristolochiaceae plant Herba Asari, Herba Asari and Seoul Herba Asari; Semen Coicis selects the kernel of grass Semen Coicis Coix lacryma-jobi L. var. meyuan (Romen.) Stapf.
The method that above-mentioned each Chinese crude drug is prepared into oral liquid is comprised the steps: to take and cleans up and the Caulis Spatholobi of drying, Rhizoma Zingiberis, Ramulus Euonymi, Pseudobulbus Cremastrae Seu Pleiones, Radix Morindae Officinalis, Folium Artemisiae Argyi, Fructus Tribuli, Fructus Arctii, Herba Asari and Semen Coicis, merge, decoct with water twice, collecting decoction, when being evaporated to 70 DEG C, relative density is 1.15-1.20, adding ethanol makes the percent by volume of alcohol content reach 75-85%, stir, leave standstill, filter, during filtrate reduced in volume to 70 DEG C, relative density is 1.10-1.20 and reclaims ethanol to obtain concentrated solution, is added water by concentrated solution and auxiliaries becomes oral liquid.
Compared with prior art, tool of the present invention has the following advantages and progress significantly: (1) good effect; Adopt traditional Chinese medicine composition for treating polycystic ovarian syndrome of the present invention to improve pregnancy rate, short ovary ovulation and menorrhea are risen, and safeguard homeostasis, improve cure rate; (2) safety is high; Because medicine of the present invention is prepared from by adopting Chinese medicine material, toxicity is low, and patient medication is safer.
Detailed description of the invention
The present invention is further illustrated below by embodiment.Embodiments of the invention are only used for the present invention is described, instead of limitation of the present invention, under concept thereof of the present invention, all belong to the scope of protection of present invention to the simple modifications of preparation method of the present invention.
Embodiment 1
Crude drug prescription: Caulis Spatholobi 3 kilograms, Rhizoma Zingiberis 1.2 kilograms, Ramulus Euonymi 3 kilograms, Pseudobulbus Cremastrae Seu Pleiones 2.2 kilograms, Radix Morindae Officinalis 2.2 kilograms, Folium Artemisiae Argyi 1.2 kilograms, Fructus Tribuli 1.2 kilograms, Fructus Arctii 1.2 kilograms, Herba Asari 2.2 kilograms, Semen Coicis 3 kilograms.
Preparation method: the medical material taking above-mentioned recipe quantity merges, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.08MPa, relative density is 1.15 when being evaporated to 70 DEG C at 70 DEG C, adds 95% (v/v) ethanol and makes alcohol content reach 75% (v/v), stir, hold over night, filter, under 0.08MPa, 65 DEG C of conditions, concentrating under reduced pressure becomes filtrate is 1.15g/mL to relative density when 65 DEG C, adds water and sucrose is mixed with oral liquid.
Embodiment 2
Crude drug prescription: Caulis Spatholobi 3.5 kilograms, Rhizoma Zingiberis 1 kilogram, Ramulus Euonymi 3.2 kilograms, Pseudobulbus Cremastrae Seu Pleiones 1.8 kilograms, Radix Morindae Officinalis 2.2 kilograms, Folium Artemisiae Argyi 1.4 kilograms, Fructus Tribuli 0.9 kilogram, Fructus Arctii 1.4 kilograms, Herba Asari 1.8 kilograms, Semen Coicis 3.6 kilograms.
Preparation method: the medical material taking above-mentioned recipe quantity merges, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.08MPa, relative density is 1.15 when being evaporated to 70 DEG C at 70 DEG C, adds 95% (v/v) ethanol and makes alcohol content reach 85% (v/v), stir, hold over night, filter, under 0.08MPa, 65 DEG C of conditions, concentrating under reduced pressure becomes filtrate is 1.15g/mL to relative density when 65 DEG C, adds water and sucrose is mixed with oral liquid.
Embodiment 3
Crude drug prescription: Caulis Spatholobi 2.6 kilograms, Rhizoma Zingiberis 0.8 kilogram, Ramulus Euonymi 2.6 kilograms, Pseudobulbus Cremastrae Seu Pleiones 2.5 kilograms, Radix Morindae Officinalis 2.5 kilograms, Folium Artemisiae Argyi 0.8 kilogram, Fructus Tribuli 1.4 kilograms, Fructus Arctii 0.8 kilogram, Herba Asari 2.2 kilograms, Semen Coicis 3 kilograms.
Preparation method: the medical material taking above-mentioned recipe quantity merges, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.08MPa, relative density is 1.20 when being evaporated to 70 DEG C at 70 DEG C, adds 95% (v/v) ethanol and makes alcohol content reach 80% (v/v), stir, hold over night, filter, under 0.08MPa, 65 DEG C of conditions, concentrating under reduced pressure becomes filtrate is 1.15g/mL to relative density when 65 DEG C, adds water and sucrose is mixed with oral liquid.
Embodiment 4 Chinese medicine composition of the present invention is to the effectiveness study of patients with polycystic ovary syndrome
57 routine patients with polycystic ovary syndrome, year mean age (26.2 ± 3.8); Marriageable age 2-9, all patients all make a definite diagnosis meet polycystic ovarian syndrome standard through B ultrasonic, gonadal hormone 6 detections.It is divided into test group and matched group at random.Wherein test group 29 example, matched group 28 example.Two groups of patients difference not statistically signigicant in age, marriageable age, the state of an illness etc., has the comparability of curative effect aspect.
Matched group patient gives spironolactone sheet 40mg, and every day 2 times is oral, serve on 20d; Diformin tablet 0.5g, every day 3 times is oral, serve on to appearance and normally to ovulate drug withdrawal.Menstrual cycle or withdrawal bleeding 5d start oral clomiphene 50mg, and every day is total to 5d 1 time, adds VITAMIN C TABLET 200mg 3 times every day simultaneously.Test group patient adds and uses Chinese medicinal formulae of the present invention on the treatment basis of matched group: Caulis Spatholobi 30g, Rhizoma Zingiberis 12g, Ramulus Euonymi 30g, Pseudobulbus Cremastrae Seu Pleiones 22g, Radix Morindae Officinalis 22g, Folium Artemisiae Argyi 12g, Fructus Tribuli 12g, Fructus Arctii 12g, Herba Asari 22g, Semen Coicis 30g.Be decocted in water for oral dose, within the 5th day, start to take in menstruation, every day 1 dose is oral at twice.Two groups of patients are all 1 course for the treatment of with 20d, 3 courses for the treatment of of continuous use.After treatment terminates, add up the curative effect of two groups of patients by following evaluation criterion:
Cure: clinical symptoms is obviously improved, occur ovulation, more than menstruation rule continuous 3 cycles or become pregnant, LH/FSH (serum follicule-stimulating hormone (FSH)/lutropin), T (serum testosterone) value decline and recover normal;
Effective: clinical symptoms is improved, and menstruation rule occurs again irregular less than 2 all after dates, LH/FSH, T value decline but do not return to normal level;
Invalid: clinical symptoms is not improved, menstrual cycle is still irregular, and LH/FSH, T value decline not obvious.
Two groups of patients are after treatment, and test group total effective rate 96.6%, apparently higher than matched group 67.9%.Concrete result of the test is in table 1.
The comparison of table 1 liang group patient clinical curative effect
Claims (4)
1. treat a Chinese medicine composition for polycystic ovarian syndrome, it is characterized in that: described Chinese medicine composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 30 parts, Rhizoma Zingiberis 12 parts, Ramulus Euonymi 30 parts, Pseudobulbus Cremastrae Seu Pleiones 22 parts, Radix Morindae Officinalis 22 parts, Folium Artemisiae Argyi 12 parts, Fructus Tribuli 12 parts, Fructus Arctii 12 parts, Herba Asari 22 parts, Semen Coicis 30 parts.
2. treat the Chinese medicine composition of polycystic ovarian syndrome according to claim 1, it is characterized in that: described Chinese medicine composition is oral formulations.
3. the Chinese medicine composition for the treatment of polycystic ovarian syndrome according to claim 2, is characterized in that: described oral formulations is oral liquid, granule, tablet or capsule.
4. the application of Chinese medicine composition described in claim 1 in the medicine of preparation treatment polycystic ovarian syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310739992.5A CN103690922B (en) | 2013-12-30 | 2013-12-30 | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310739992.5A CN103690922B (en) | 2013-12-30 | 2013-12-30 | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103690922A CN103690922A (en) | 2014-04-02 |
| CN103690922B true CN103690922B (en) | 2015-08-19 |
Family
ID=50352692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310739992.5A Active CN103690922B (en) | 2013-12-30 | 2013-12-30 | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690922B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168418A (en) * | 2015-10-14 | 2015-12-23 | 刘瑞莲 | Composition for treating polycystic ovarian syndrome and preparation method |
| CN105663836A (en) * | 2016-02-26 | 2016-06-15 | 李晓峰 | Pharmaceutical composition for preventing polycystic ovarian syndrome polycystic ovarian syndrome recurrent spontaneous abortion |
| CN116211900B (en) * | 2023-03-28 | 2023-12-22 | 微康益生菌(苏州)股份有限公司 | Microecological viable bacteria preparation for improving polycystic ovary syndrome, and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496862B (en) * | 2009-03-19 | 2011-04-13 | 王新民 | Chinese medicinal composition for treating infertility and preparation method thereof |
| CN101912511B (en) * | 2010-08-09 | 2011-11-23 | 杨素梅 | Chinese medicinal preparation for treating qi-blood deficiency polycystic ovary syndrome |
| CN102319405B (en) * | 2011-09-30 | 2013-03-13 | 张鸿翔 | Traditional Chinese medicine composition for treating polycystic ovary syndrome |
-
2013
- 2013-12-30 CN CN201310739992.5A patent/CN103690922B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103690922A (en) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112891399A (en) | Traditional Chinese medicine composition and application and preparation method thereof | |
| CN104758825A (en) | Traditional Chinese medicine composition for treating amenorrhea | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103690922B (en) | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN102626478A (en) | Externally used Chinese herbal medicine compound for treating lumbar muscle strain for years | |
| CN101912567B (en) | Chinese medicinal prescription for treating chronic myocarditis | |
| CN101579405B (en) | Traditional Chinese medicine for curing constipation and preparation method thereof | |
| CN100509025C (en) | A medicine for treating diabetes | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN1160108C (en) | Medicine for treating cholecystitis and its preparing process | |
| CN1246031C (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN102784129A (en) | Preparation process of traditional Chinese medicine plaster | |
| CN102688434A (en) | Traditional Chinese medicine (TCM) for treating diabetes | |
| CN103071079B (en) | Traditional Chinese medicinal composition for treating prurigo nodularis | |
| CN102743658B (en) | Traditional Chinese medicinal composition for treating urticaria | |
| CN100411672C (en) | A medicinal composition for treatment of psoriasis | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus | |
| CN103893621A (en) | Traditional Chinese medicament for treating senile vaginitis | |
| CN104162043A (en) | Traditional Chinese medicine used for treatment of allergic nodular cutaneous vasculitis | |
| CN103566219A (en) | Traditional Chinese medicine composition for treating cold | |
| CN103585580A (en) | Chinese medicinal preparation for treating recurrent oral ulceration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhou Yanbin Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: ZHOU YANBIN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170503 Address after: 226200 Hopewell Town, Qidong, Jiangsu, Nantong Patentee after: Qidong Jiulong shunzhou toy factory Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Patentee before: Wang Xueyan |